An investigation into the use of bilirubin oxidase to measure the apparent concentration of unbound bilirubin in solutions of bilirubin or bilirubin! human serum albumin demonstrated (1) near linearity of oxidation rate with bilirubin concentration up to 16 IJ.moVL, (2) linearity with respect to enzyme concentration up to 75 mgIL, (3) specificity of the enzyme for unbound bilirubin, as opposed to bound bilirubin, (4) poor precision. Very small absorbance changes leading to poor precision and the potential for interference by conjugated bilirubin meant that the method was unsuitable for patient samples.
Unbound unconjugated bilirubin is toxic to nerve tissue, but its concentration is normally kept below toxic levels by avid binding to serum albumin. Elevation of the unbound bilirubin concentration in neonatal jaundice, when albumin binding sites approach saturation, is considered to be responsible for damage to brain cells, leading to bilirubin encephalopathy and kernicterus. 1 Unbound bilirubin concentrations have been measured by Sephadex G-25 filtration, in which unbound bilirubin is retained on the column," or enzymatically using horse radish peroxidase which catalyses the oxidation of bilirubin by hydrogen peroxide. Excess albumin inhibits the oxidation due to albumin-bilirubin complex formation. The equilibration of bilirubin and albumin is very rapid compared to the rate of oxidation of unbound bilirubin and therefore, the initial rate of bilirubin oxidation is proportional to the unbound bilirubin concentration." The problem caused by degradation of hydrogen peroxide by catalase activity in serum can be overcome by sUbstitutin~ethyl hydroperoxide for hydrogen peroxide-or by generating hydrogen peroxide in situ using glucose and glucose oxidase." Bilirubin oxidase (BOX; absorbance reading on the Cobas Bio cannot be taken at less than 10 s after mixing, so an LKB 2086 Kinetic Analyser (LKB Instruments Limited, South Croydon, Surrey, UK) was used to follow the initial rate of reaction. All assays were carried out at 37°C. Optical density was measured at 440 nm on the SP1750 and Cobas Bio. Only a 410 nm filter was available for the LKB analyser. At this wavelength bilirubin absorbs about half as much as at 440 nm. This disadvantage is compensated by the ability to measure initial rates during the first 10 s of the reaction.
REAGENTS

Buffer
Tris-HCI buffer, 0·1 mol/L, pH g·O, was used in most assays. For the pH profile and enzyme stability studies tris-HCI buffers, 0·1 moVL, pH 6·5-8·9, and 0·1 mol/L citrate-phosphate buffers, pH 5·0 and 6·0 were also used.
Bilirubin solutions
Bilirubin was dissolved in 10 mmoVL sodium hydroxide and then diluted in 0·1 moVL tris-HCI, pH g·O, unless otherwise stated to give the desired concentration (50 to 1200 I1moVL). These solutions were freshly prepared, or stored in the dark at 4°C. Albumin when present was dissolved in 0·1 moltL tris-HCI, pH g·O, before addition to the bilirubin solution.
BOX reagent BOX was dissolved in the appropriate assay buffer to give a stock solution of the desired concentration (0·5-7 mg/ml). With the exception of the stablilty study this was diluted with assay buffer immediately before use (typically 1 in 100 dilution).
PROCEDURE
Typical assay conditions for the three instruments were as follows. For the Unicam SP1750 spectrophotometer 2 mL buffer was added to 100 !JL sample and the reaction initiated by addition of 30 ul, BOX reagent: for the Cobas Bio analyser, 220 ilL reagent (buffer plus BOX reagent) was added to 10 ilL sample and 20 ul, diluent (distilled water). For the LKB kinetic analyser, 1 mL buffer was added to 10 ilL sample and the reaction initiated by addition of 100 !JL BOX reagent.
Results
BOX STABILITY
Previous investigation showed BOX not to be stable'' although in that study storage conditions were not investigated. A more convenient assay would result if stable storage conditions could be found. The effect of pH and temperature on the stability of BOX was. therefore, investigated. BOX solutions (70 mg/L) were prepared by diluting a stock solution 1 in 100 with 0·1 moVL citrate-phosphate or tris-HCI buffers in the pH range 5·~·9. Aliquots were stored at 4°C and at -20"C and were tested at intervals for 1 month. The assay buffer was 0·1 moVL tris-HCI. pH 8·0, and the final concentrations of bilirubin and BOX were 35 I1moVL and 1 mgIL, respectively. Preliminary experiments had shown that there was no change in absorbance in the absence of BOX. BOX solution was shown to be stable at 4°C for at least 1 month at pH 8,9, for at least 4 days at pH g·O, and for less than 2 days at pH 5-7. None of the solutions stored frozen were found to be stable.
PH OPTIMUM
The optimum pH was found to be 8·0 (see Fig. 1 ). All subsequent assays were carried out in 0·1 moVL tris buffer. pH 8·0.
I.INEARITY WITH BILIRUBIN CONCENTRATION
The proposed assay was based on the principle that bilirubin that is not bound to albumin reacts with BOX, whereas albumin-bound bilirubin does not. Theoretically, BOX could be used to measure free bilirubin in an end-point or a kinetic mode. In the end-point mode the reaction is allowed to go to completion and the 20 16 ,., Q >< 12 c:
Effect of pH on bilirubin oxidase activity. BOX (UX) ,...L of 11-1 mglL) was added at 37"C to I mL of bilirubin (5,6 ,...moIlL) in 0·1 mollL tris-HCI buffer at the indicated pH. The absorbance at 410 nm was continuously monitored for I min. The initial linear rate of absorbance change is plotted. difference in absorbance represents the unbound fraction. In the kinetic mode the rate of change of absorbance is proportional to the free bilirubin concentration. Initial experiments suggested that BOX could oxidise (at a slow rate) albumin-bound bilirubin and therefore, the end-point mode could not be used. To develop a viable kinetic method it was necessary to demonstrate that the rate of oxidation was proportional to bilirubin concentration. Michaelis-Menten kinetics predicts a hyperbolic relationship between substrate concentration and activity with first order kinetics at concentrations low relative to the K m • We observed a sigmoidal relationship (Fig. 2) . If a concentration of 2 J.lM was chosen to standardise the assay, this would lead to up to a 10% error in the free bilirubin concentration. This, while not being desirable, need not invalidate the assay.
LINEARITY WITH BOX CONCENTRATION
At the low free bilirubin concentrations that are present in plasma, the rate of absorbance change is small. To increase this to a measureable rate. higher concentrations of BOX are required than are necessary for the measurement of the rate of change of absorbance in the absence of albumin. It was. therefore. necessary to demonstrate that the rate of oxidation of bilirubin is proportional to BOX concentration.
For a final bilirubin concentration of 2 umol/L, the initial rate of oxidation of bilirubin was proportional to BOX concentration up to 75 mg/L. For a final bilirubin concentration of 5 umol/L, the initial rate of oxidation of bilirubin was proportional to BOX concentration up to 25 mg/L.
EFFECT OF ALBUMIN
The specificity of BOX for non-albumin bound bilirubin was investigated. At a molar ratio of bilirubin to albumin of less than one. when there would be little free bilirubin. there was little oxidation of bilirubin. Only when this ratio was exceeded. leading to substantial free bilirubin. was bilirubin available for reaction with BOX ( Fig. 3 ).
OXIDATION OF CONJUGATED BILIRUBIN
Conjugated bilirubin is more soluble than unconjugated, thus is more likely to form a substrate for BOX in the presence of albumin. This would lead to an over-estimate of free bilirubin in the presence of conjugated bilirubin. This possibility was investigated. Rat bile is known to contain bilirubin only in the conjugated form. This was confirmed by demonstrating its complete extraction into the polar phase of a Weber-Schalm partition. Rat bile was diluted either with assay buffer, or with a solution of albumin in buffer to give a bilirubin concentration of 35 umol/l, and a bilirubin to albumin molar ratio of approximately 0·1. The rate of oxidation of bilirubin in the albumin-diluted bile was approximately one quarter of the rate in the buffer-diluted bile (using a BOX concentration of 100 rng/L). Using similar concentrations of unconjugated bilirubin the rate of oxidation by BOX in the presence of albumin was less than 0·1% of the rate in its absence. Thus interference by conjugated bilirubin is a potential problem of the assay. PRECISION Precision studies were carried out on the LKB at two concentrations of bilirubin. Solutions were prepared daily from pre-weighed aliquots of bilirubin which were dissolved in 10 mM NaOH and made up to 3·08 mL with assay buffer to give a 555 umol/L solution (equivalent to 5 umol/L in the cuvette). This solution was diluted 1 in 2·5 with buffer to give a solution equivalent to 2 umol/L in the cuvette. A BOX concentration of 1 mglL was used in all assays. Results were expressed as the decrease in absorbance at 410 nm per min, per umol/l, of bilirubin, per mg/L of BOX.
WITHIN-BATCH IMPRECISION
On each of several days replicate analyses were carried out on the two bilirubin solutions, and the coefficient of variation for each day was calculated (see Table 1 ).
BETWEEN-BATCH IMPRECISION
This was calculated from the first result of each set of replicate analyses on each day (see Table  2 ).
APPUCATION TO PATIENTS' SAMPLES
Icteric plasma samples were stored at -20"C if not assayed immediately. In an initial experiment eight plasma samples were assayed in duplicate. Plasma blanks. without BOX, showed rates of decrease of absorbance which were less than those in the presence of BOX, confirming that the absorbance changes were due to enzyme activity. The initial velocity (measured over a minimum of 10 and a maximum of 50 s) corresponded to decreases in absorbance per minute at 410 nm ranging from 0·002 to 0·017. To achieve even these low absorbance changes required 100 mg/L BOX; a concentration which is beyond the linearity limit of 75 mg/L determined using bilirubin solutions (see above). Furthermore, with most spiked plasma samples, in which a greater absorbance change was observed, the response was not linear above 25 mg/L BOX. Use of this concentration with unspiked plasma samples would have led to almost undetectable absorbance changes. The method is, therefore, not suitable for the measurement of unbound bilirubin in plasma samples.
Discussion
We have attempted to develop an assay for non-albumin bound bilirubin by using the enzyme bilirubin oxidase which oxidises bilirubin that is not bound to bilirubin. Despite a good theoretical basis for the method and despite demonstrating its feasibility, we have encountered severe difficulties in developing an assay. Using solutions of bilirubin and albumin the method was poorly reproducible and problems were encountered in applying the method to patients' samples. The poor precision is probably the result of the very low absorbance changes «O·Ollmin) being measured. It is not possible to increase this by increasing the sample size since with a ligand such as bilirubin which is avidly bound to protein, dilution of a sample does not have a significant effect on its unbound concentration." Thus, when a plasma sample is diluted for the assay of unbound bilirubin, the cuvette concentration of unbound bilirubin is the same as that in the original sample. Neither is it possible to increase the absorbance change by increasing the BOX concentration as the response to increasing BOX concentration was non linear.
In the peroxidase method of Jacobsen and Wennber~the enzyme concentration used for the analysis of plasma is 800 times that used for standard albumin-free bilirubin solutions. Similarly, Nakamura and Lee 4 use WOO times more enzyme for plasma analysis. Neither of these authors demonstrated that the response to enzyme concentration was linear to the extent assumed. However, using such enzyme concentrations both authors achieved a measurable absorbance change. In the example shown by Jacobsen and Wennberg,3 a sample with a total bilirubin concentration of approximately 200 J.Ul1oVL gave an absorbance change per minute of approximately 0·05. In the example illustrated by Nakamura and Lee 4 a sample with a total bilirubin of about 340 J.Ul1oVL gave an absorbance change per minute of about 0·085. The only other way of increasing the absorbance change is by increasing the path length. This would not be practical for most modem analysers.
In addition conjugated bilirubin appears less avidly bound to albumin and thus leads to positive interference in both the peroxidase method' and the present method. In view of these problems, bilirubin oxidase used as described cannot be recommended for the assay of the apparent unbound bilirubin concentration in human plasma.
